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Label-free detection of hypoxia-
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Nanoscale extracellular vesicles (EVs) including exosomes (50–150 nm membrane particles) have 
emerged as promising cancer biomarkers due to the carried genetic information about the parental 
cells. However the sensitive detection of these vesicles remains a challenge. Here we present a label-
free electrochemical sensor to measure the EVs secretion levels of hypoxic and normoxic MCF-7 
cells. The sensor design includes two consecutive steps; i) Au electrode surface functionalization for 
anti-CD81 Antibody and ii) EVs capture. The label-free detection of EVs was done via Differential Pulse 
Voltammetry (DPV) and Electrochemical Impedance Spectroscopy (EIS). The working linear range for 
the sensor was 102–109 EVs/ml with an LOD 77 EVs/mL and 379 EVs/ml for EIS and DPV based detection. 
A blood-abundant protein, RhD was used for the selectivity test. In order to assess the performance of 
the biosensor, the level of EVs secretion by the human breast cancer MCF-7 cell line was compared with 
enzyme-linked immunosorbent assays (ELISA) and Nanoparticle Tracking Analysis (NTA). Designed 
label-free electrochemical sensors utilized for quantification of EVs secretion enhancement due to 
CoCl2-induced hypoxia and 1.23 fold increase with respect to normoxic conditions was found.
Extracellular vesicles (EVs) are widely recognised due to their significant contribution to intercellular com-
munication via protein, lipid and RNA transport from parent cell to recipient cell1,2. The classification and 
nomenclature of EVs are still being defined due to ongoing debate regarding biogenesis and associated bio-
logical processes1–4. EVs are usually characterized and quantified by well-known exosomal biomarkers such as 
tetraspanins CD-9, CD-64, CD-81, CD-53, CD-37 and cytosolic proteins of Tsg101, Alix, or cytoskeletal pro-
teins1–4. In addition to those characteristic protein cargos, EVs also carry genetic information via DNA, coding/
non-coding RNA like miRNAs5.
Paramount amount of research showed the potential use of EVs in the clinic due to their antitumoral immune 
response stimulation, induction of tolerogenic effects and involvement in metastatic processes6,7. In addition to that, 
EVs are present in most bodily fluids, therefore are considered as non-invasive biomarkers for early cancer detection 
and monitoring treatment efficacy8 which are present in blood in concentrations ranging from 108 to 1011 EVs/ml9.
Breast cancer, one of the leading causes for malignancies in women, has recently been associated with EVs due 
to EVs -mediated tumor angiogenesis stimulation, drug resistance promotion and re-establishment of tumour 
microenvironment via reorganization of stroma10. In addition to those biological functions, it is reported that, 
hypoxia-induced EVs release could be one of the reasons for malignant transformation followed by proliferation 
and migration, since enhanced HIF-1α (Hypoxia-inducible factor 1-alpha) shown to increase EVs release and 
resulted in an aggresive cell phenotype11. Therefore, EVs hold great promise as non-invasive biomarkers for breast 
cancer diagnosis, progression and monitoring treatment efficiency8,10. In addition to this, EVs will also play a role 
in the creation and verification of in in vitro models of cancer, aiding in the development of therapeutical drugs. 
This highlights the importance of detecting EVs from conditioned medium. However, isolation and quantifica-
tion of EVs are still challenging. Ultrancentrifugation has been accepted as the golden standard for purification 
and isolation of EVs whereas western blot analysis and enzyme-linked immunosorbent assays (ELISA) have been 
used for analysis and detection purposes. Drawbacks associated with these techniques such as time consumption, 
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large sample volume requirement and labelling steps necessitates novel techniques for easy, label-free and sensi-
tive EVs detection and analysis12.
Up to now, various sensing technologies have been developed for detection and profiling of exosomes13. 
Plasmonic sensing systems based on surface plasmon resonance (SPR)14–16 have been shown to provide label-free 
sensing schemes with minimal sample volume as low as 0.3 μl. Electrochemical sensors offer advantages in EVs 
sensing due to their miniaturization capability, affordable cost and high detection limits17–22. Most of the sensors 
developed so far provided a proof-of-concept for EVs sensing with defined limit of detection (LOD), with the 
exception of a few, which have been applied to analyse clinical samples or study a biological question16,18,23,24. 
However, considering the final aim of these biosensors, it is crucial to test their performance for a specific bio-
logical context.
With this work, for the first time in literature, we aim to demonstrate a label-free, electrochemical biosensor 
that is able to detect the increased EVs release from breast cancer cell line, MCF-7 due to CoCl2 induced hypoxia11. 
The principle behind the biosensor involves the monitoring of changes in electrochemical signals due to bio rec-
ognition reaction between anti-CD81 antibody and CD-81 present on the lipid membrane of breast-cancer EVs. 
The designed disposable, simple EVs biosensor provides the best detection limit (LOD) of 77 EVs/ml to the best 
of our knowledge among others reported in literature and has the dynamic detection range of 102–109 EVs/ml. 
Thanks to its lower LOD compared to any other electrochemical EVs biosensors in literature, and its selectivity 
against CD-81 tested with one of the most abundant blood protein, RhD, the proposed biosensor holds great 
potential for not only detection of EVs from blood samples but also for integration with platforms that mimic 
tumor microenvironment for chemotherapeutic drug testing.
Methods
Chemicals and reagents used. MCF-7 cell line was purchased from ATCC ATCC. RPMI 1640 + 
GlutaMAXTM, Fetal Bow Serum (FBS), Penicillin/Streptomycin (Gibco- 151140122) and insulin (Gibco 12585-014) 
were bought from Gibco, Life Technolgies. Immunostaining reagents; HIF-1 α antibody, 2-(4-amidinophenyl)-1H 
-indole-6-carboxamidine (DAPI, D21490) was purchased from Invitrogen, Alexafluor 488 were provided by histology 
core facility in Life Sciences department of EPFL. Cobalt chloride, CoCl2 (C8661) and other chemicals were purchased 
from Sigma. Gold screen-printed electrodes (Au SPE) used throughout the study were bought from Dropsens.
Electrochemical Measurements. Measurements of EIS/DPV were performed using an electrochemical 
working station (Metrohm Autolab PGSTAT 302 N with Nova 1.11 software) with a conventional three-electrode 
system. For EIS, the potential was set to 0.100 mV and the frequency was scanned in a range of 10−1 to 105 kHz 
at a 0.005 mV of AC amplitude. For DPV measurements, potential was scanned from −0.2 V to + 0.5 V with a 
step potential of 0.002 V/s. For both DPV and EIS measurements, an equimolar solution of 5 mM K3[Fe(CN)6]/
K4[Fe(CN)6] in 0.1 M KCl was used for all electrochemical measurements.
Immobilization Process for Antibody Biosensor. Electrodes were cleaned with PBS and ethanol prior 
to their use. Afterwards Au SPEs were immersed in a solution of 10 mM of 11-marcaptoundenoic acid (11-MUA) 
for 1 hour at room temperature to generate a thiol terminated self assembly monolayer (SAM). After washing 
the surface with ethanol and PBS, the electrodes were incubated in a EDC (50 mM)/NHS (50 mM) solution for 
30 minutes at room temperature. After this step, the Au SPE surface was exposed to 600 μg/mL of neutravidin 
(Thermofisher Scientific) for 1 hour at 4 °C. Then, 5.5 ug/mL of biotinylated anti-CD81 antibody (Miltenyi Biotec) 
solution was incubated on the electrodes for 16 hours at 4 °C.
Cell Culture and Treatment. MCF-7 cells were maintained in RPMI 1640 + GlutaMAXTM supplemented 
with 10% HI FBS, 1% Penicillin/Streptomycin and 10 μg/mL of human recombinant insulin (ThermoFisher 
Scientific) in a standard culture incubator with humidified air containing 5% CO2 at 37 °C. For EVs studies, FBS 
free of EVs was used. EVs free FBS was prepared through an 18 hours ultracentrifugation at 4 °C and 100 000 × g. 
Cells were seeded at 1.5 × 106 per well in 6-well plates in the day before the experiment. The next day, medium 
containing 200 μM of CoCl2 was added to the cultures, using normal medium as control. Cell counting was per-
formed with a haemocytometer and viability was assessed with the trypan blue exclusion method.
EVs Isolation and Purification. EVs isolation was performed as previously described25. Briefly, cell culture 
supernatants were centrifuged at 300 × g for 5 minutes. The supernatants were transferred to a clear tube and cen-
trifuged at 2000 × g for 10 minutes, followed by centrifugation at 10 000 × g for 30 minutes. The supernatants were 
passed through a 0.22 μm filter and were ultracentrifuged for 2 hours at 100 000 × g. After discarding the super-
natant, the pellets were resuspended in PBS and ultracentrifuged for 2 hours at 100 000 × g. The pellet was resus-
pended in 1 mL of PBS and stored at 4 °C for analysis performed within a week or −20 °C for long-term storage.
EVs Nanoparticle Tracking Analysis (NTA). The analysis of absolute particle distribution was performed 
using the NanoSight NS300 (Malvern Panalytical). The NTA measurement conditions were: temperature = 22 °C; 
viscosity = 0.95 cP; frames per second = 21, measurement time = 91 s. Three records were performed per sample.
Immunocytochemical Assay. MCF-7 grown on 96 well-plates were fixed with 4% paraformaldehyde in 
PBS for 20 min at room temperature, washed with PBS, permeabilized with 0.1% Triton X-100, washed with PBS 
and blocked with 1% bovine serum albumin in PBS. Cells were incubated overnight with anti HIF1-α antibody 
(Abcam) at 1:200 dilution, washed with PBS, and incubated for 1 hour at room temperature with secondary anti-
body at 1:200 dilution. Samples were washed with PBS and counter stained with DAPI. Fluorescent images were 
obtained with a Zeiss LSM700 confocal microscope and processed using ImageJ.
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Enzyme-Linked Immunoabsorbant Assay. An ELISA kit for CD-81 Ab based detection of EVs was pur-
chased from System Biosciences. After purification of EVs as decribed above, samples were processed according 
to manufacturer’s instructions.
Statistical Analysis. All data were obtained from three independent experiments, and expressed as means ± SD. 
One-way ANOVA was used to compare data from different experimental groups and the difference between them was 
estimated by the least significant difference (LSD) test. p < 0.05 was considered statistically significant.
Results
The conceptual drawing of the experimental steps was depicted in Fig. 1. The effect of hypoxia/normoxia condi-
tions on EVs secretion level was investigated by label-free electrochemical biosensors upon detection of CD-81 
EVs surface biomarker via DPV and EIS methods. These two approaches were used since both methods have 
advantages and disadvantages over each other, such as being fast as in the case of DPV but having the compromise 
between being less destructive and taking longer time for the measurement for EIS. Prior to detection, EVs were 
isolated from cell culture supernatant via ultracentrifugation as detailed in section 2.2 and characterized via NTA 
in terms of concentration (number of EVs/ml) and size. Experimental results regarding label-free detection of 
EVs at different culturing conditions are discussed in the following section.
Isolation of EVs from MCF-7 cell line. The isolation of cancerous EVs was performed through ultracentrifuga-
tion as described in methods section. Nanoparticle tracking analysis measurements gave a size distribution with a mean 
diameter of 171.6 ± 51.7 nm, in the expected size range as can be seen in Fig. 2A. Considering the two peaks in the 
NTA graph, and mean diameter of 171.6 nm, our sample contain heteregoneous mixture of exosome and microvesicles 
including ectosomes, membrane particles and apoptotic vesicles as a typical result of high-speed ultracentrifugation 
protocols reported elsewhere26,27. Therefore, as other biosensor papers in literature28,29, in this work we will use EVs as 
a more general term. Similar to other optical30 and electrochemical biosensors17,24 designed for EVs detection, in our 
work we assumed that the EVs suspensions are monodisperse with a mean diameter, obtained from the NTA analysis. 
Figure 2B shows the real time captured image of NTA analysis where EVs seem as white circles.
Electrode functionalization with biotinylated anti-CD81 antibody. As a first step of biosensor devel-
opment, the commercially available gold screen printed electrode (Au-SPE) surface was functionalized for bioti-
nylated anti-CD81 capture. To do that, self-assembly monolayer (SAM) was immobilized on the sensor surface via 
immobilization of 11-mercaptoundodecanoicacid followed by N-ethylcarbodiimide (EDC)/ N-hydroxysuccinimide 
(NHS) interaction for neutravidin capture31,32. Neutravidin has been chosen due to its key features as being car-
bohydrate free, neutral isoelectric point that minimizes non-specific binding. After neutravidin immobilization, 
biotinylated anti-CD81 was incubated on the electrode surface for the strong covalent binding between biotin and 
neutravidin. Characterization of the electrode surface upon each functionalization step was done by EIS and DPV. 
The complex impedance data recorded by EIS measurements were presented by Nyquist plots whereas voltam-
metric measurements were presented in differential pulse voltammograms, as can be seen in Fig. 3A,B. As typical 
Nyquist plots modelled according to Randles’ circuit which is composed of solution resistance (Rs), charge transfer 
Figure 1. Experimental steps followed throughout the work. MCF-7 cells were exposed to either CoCl2- 
induced hypoxic or normoxic conditions. Isolation of EVs were done via ultracentrifugation. Characterization 
and quantification of EVs were done via NTA and EVs biosensors that are designed to capture CD-81 EVs 
biomarker via biotinylatd anti-CD81 antibody immobilized through streptavidin-biotin interaction on SAM 
modified Au SPE surface.
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resistance (Rct) and double-layer capacitance (Cdl), Fig. 3A shows the change in the imaginary component of imped-
ance (|−Z″|, capacitance based) as a function of the real component (Z′, resistance based) of impedance with respect 
to different functionalization steps. The Rct value that corresponds to the diameter of semi-circular Nyquist plots 
increased after each functionalization step due to increased blockage of the redox probe, Fe(CN)6]3/4 through AuSPE 
surface. Expectedly, anodic current of redox probe (IpA) decreases upon successive immobilization of biotinylated 
anti CD81-Ab and EVs as shown by the differential pulse voltammogram represented in Fig. 3B.
Sensitivity of the biosensor. Having seen the successful functionalization of the sensor surface, we have 
tested various CD-81 marked MCF-7 EVs concentrations (1 × 101 to 1010 EVs/mL) to determine the sensitivity 
of the biosensor. Altough the detection of EVs was achieved in a concentration-dependent manner based on 
capturing surface exposed CD-81 proteins, it is very important to ensure uniform size distribution for EVs since 
electrode surface saturation would be affected depending on the size of vesicles. To ensure uniform size distribu-
tion, exosome solutions were mixed gently before its use.
EVs are negatively charged in hydrophilic buffers33. The peak shift to more positive values with respect to 
increasing exosome concentration (Fig. 4A) is attributed to the fact that the electron transfer becomes slower 
due to decreased diffusion coefficient and hence a greater potential is required to overcome the kinetic barrier. 
Similarly, due to steric hindrance of EVs, access of Fe(CN)6]3/4 to electrode surface become more difficult and as 
a result, oxidation peak current decreases. A similar approach was used by Shiddiky et al.19 who compared the 
exosome secretion levels of normal and cancerous cells based on DPV signal of Fe(CN)6]3/4.
Calibration curves (Fig. 4C,F) were drawn according to normalized Rct values (Normalized Rct = (Rct)EVs/
(Rct)Ab) derived from EIS data (Fig. 4D) and normalized IpA values (Normalized IpA = (IpA)EVs/(IpA)Ab) recorded 
by DPV data (Fig. 4A). The reason of using normalized data is the change in bare electrode Rct and IpA values due 
Figure 2. Characterization of EVs via NTA. Size distrubution analysis of EVs as a function of particle 
concentration. (A) Representative image used for size distribution analysis of extracellular vesicles (scale bar 
represents 200 nm).
Figure 3. Electrochemical characterization of the surface functionalization based on EIS (A) and DPV (B) 
according to the steps detailed in section 2.3.
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to variability in surfaces from electrode to electrode. Concentration signal curves were fitted to calibration lines 
and the linear regression equation for analysing EVs in MCF-7 cell line was found to be
Normalized Ip 0 1002 log(EVs concentration) 1 119 (1)A = − . + .
for DPV and
Normalized R 2 420 log(EVs concentration) 4 860 (2)ct = . − .
for EIS measurements with a correlation coefficient (R2) of R2 = 0.95 and 0.90 respectively. The linear dynamic 
range for both methods was found to be 102−109 EVs/ml. The relative standard deviation (%RSD) of the meas-
urements showed good reproducibility (<9.6%) using three measurements. The limit of detection (LOD) was 
calculated as 77 EVs/mL and 379 EVs/ml for EIS and DPV based detection, respectively. LOD was calculated 
according to the formula34
= +y y 3SD (3)n lLOD bla k b ank
where the average normalized signals of the lowest EVs concentration was used as yblank and the SD of the meas-
urement was used as SDblank.
These findings clearly show that, the designed label-free electrochemical biosensor is very sensitive for detect-
ing EVs considering the reported concentration of EVs in cancer patient plasma as 5.6 × 1010 EVs/ml35. Moreover, 
our biosensor has achieved the best sensitivity compared to recently reported electrochemical17,20,21,24, optical16,18,23 
and other conventional methods such as western blot36 (see Table 1). In addition to the lowest LOD, our method is 
label-free as contrary to other methods that require enzyme labels such as TMB20,22 and requires neither expensive 
equipment nor laborious experimental steps. In addition, we have used  low cost, disposable screen printed elec-
trodes that provided reproducible results without any need for expensive microfabrication procedures.
ELISA measurements. In order to compare the LOD of the biosensor, we have performed ELISA meas-
urements Calibration curves for ELISA measurements were fitted to Sigmoidal, 4 parameter logistic regression 
(4PL), where X is the log(EVs concentration) (Fig. 5). The limit of detection (LOD) of ELISA was calculated as 
8.34 × 109 EVs/ml according to the method previously used to calculate the LOD of the developed sensors.
Electrochemical measurements have been repeated with ELISA standards to show that, the standards, i.e. 
CD81 antigen, do not give the same response as the EVs and would lead to a wrong interpretation. This would 
make it incorrect to quantify the amount of EVs through the calibration curve drawn by standard samples. As 
can be seen in Fig. 5A,C, calibration curve equations of DPV and EIS based detection are different than the ones 
Figure 4. Assessment of biosensor sensitivity via concentration studies. Differential pulse voltammograms 
recorded for various EVs concentrations (10–1010 EVs/ml) (A), bar graphs represent the average IpA of redox 
probe at each concentration, (B) semi-log calibration curve drawn for DPV based detection of EVs in the 
concentration range of 102–107 EVs/ml (C). EIS measurements in the concentration range of 102–5 × 106 EVs/
ml (D), bar graphs with represent the average Rct of redox probe at each concentration (E) Semi-log calibration 
curve drawn for EIS based detection of EVs (F). Data are expressed as mean ± SD of three measurement. 
Experimental steps are detailed in methods section.
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represented in Fig. 4C,F respectively. As a result, calculated limit of detection (LOD) for the biosensor has varied 
from 1.44 × 103 EVs/ml to 77 EVs/mL for DPV technique considering standard and EVs samples respectively. On 
the other hand, LOD was calculated for EIS method as 3.96 × 105 EVs/ml for standard and 379 EVs/ml for EVs 
samples. We think that the reason to this abrupt change between standard and EVs samples is the change in size 
as well as the affinity of real and synthetic CD-81 tetraspanin/peptide to CD-81 antibody.
As can also be deduced from these results, electrochemical label-free biosensors offered better sensitivity and 
limit of detection compared to standard ELISA technique. Moreover, DPV based detection seemed to be more 
promising in terms of providing more sensitive analysis.
Biosensor selectivity. The assesment of the biosensor selectivity was done via control studies where a con-
trol protein was immobilized on Anti-CD-81 Ab immobilized Au-SPEs. We have chosen RhD as control since it 
is known to be abundant in blood as an erythrocyte membrane protein. To be sure that there are no non-specific 
binding-related false signals, a high protein concentration of RhD was chosen and tested on the developed biosen-
sors. Control study results are represented by Fig. 6. We have performed the same experimental steps to functional-
ize AuSPE surface with antiCD-81 antibody and instead of immobilizing EVs, RhD solutions were drop casted and 
incubated on functionalized electrode surface. As it can be clearly seen by Fig. 6A, RhD does not impede any changes 
on the Rct value compared to antiCD-81 antibody (Fig. 6A inset shows more clearly almost overlapping Nyquist plots 
of RhD and AntiCD81exposed Au SPEs) whereas when even a lower concentration of EVs were used as a sample, 
the Rct value was increased to 10-fold. Similarly, differential pulse voltammograms shown by Fig. 6C depicts the 
striking difference between EVs and RhD in terms of their effect on both oxidation peak current and potential. RhD 
did not affect neither the peak current nor the potential of Fe(CN)6]3/4 in a significant extent. However, voltammo-
grams recorded for EVs detection showed a different tendency since the peak potential were shifted to more positive 
values and peak current were reduced to 6-fold compared to the value recorded for antiCD-81 modified AuSPE. 
Therefore, we conclude that, our sensor showed a very good selectivity towards CD81.
Effect of CoCl2-induced hypoxia on the proliferation of the MCF-7 cell line. As it is reported by Wu 
et al., hypoxia can be induced via addition of 100 μM CoCl2 to growth media of MCF-7 cells37 on the second day of 
incubation. Exposure to CoCl2 leads to stabilization of hypoxia inducible factors such as HIF1-α, which promote the 
expression of genes related with oxygen transport, when binding to its promoter. During hypoxia, hypoxic signalling 
Sample Target antibody Method Detection range, LOD Reference
Ascites samples from ovarian 
cancer patients CD24 and EpCAM
Nanoplasmonic detection based on 
transmission spectral shifts
1 × 107 EVs/ml (3,000 
EVs in 0.3 μl of sample 
per channel/marker)
16
Ovarian cancer patient plasma CA-125, EpCAM, CD24 Fluorescence CCD imaging 7.5 × 105 particles/ml 39
hepatoma cell lines MHCC97H/L 
and mouse melanoma cell lines 
B16-F1/10
CD9, CD41b and MET SPR imaging not mentioned 15
HepG2 cell line CD63 SPR analysis and electrochemical detection of redox label 1 × 10
6 particles/ml 17
MCF-7 cell line CD9 Amperometric detection based on enzymatic conversion of TMB 2 × 10
5 particles/ml 20
Embryonic kidney HEK293 cell 
lines CD81 EIS 1.9 × 10
5 particles ml 21
MCF-7 cell line CD63 H2O2-mediated oxidation of TMB 5.2 × 105 particles/ml 22
BT474 and MDA-MB-231 cell line CD9, CD63 and HER2 SPR 3.3 × 107 particles/ml 40
MCF-7 cell line CD81 Label-free detection via DPV and EIS 77 particles/ml for DPV and 379 particles for EIS This work
Table 1. List of reported EVs biosensor platforms.
Figure 5. Calibration curves drawn by ELISA standards based on DPV (A) EIS (B) and ELISA (C). Data are 
expressed as mean ± SD of three measurements. Experimental steps are detailed in methods section.
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is activated by dimethyloxalylglycine and as one of the HIF family isoforms, HIF1-α is stabilized to regulate the 
genes that are involved in oxygen transport38. Hence, to screen hypoxia, HIF1-α is routinely detected.
After exposure to hypoxic conditions for 24 hours, the cell culture medium was processed through ultra-
centrifugation and its concentration was obtained through a NTA analysis. The absolute number of EVs was 
normalized to the live cell number and NTA results showed higher EVs in the case of hypoxic condition. MCF-7 
cells showed similar morphology both in hypoxia and normoxia as shown in Fig. 7A-a and Fig. 7A-b respectively. 
Total and viable cell counts represented by bar graphs in Fig. 7A-c prove that CoCl2 exposure doesn’t affect cell 
viability for the experimental duration (3 days). Expression of HIF-α was assessed through immunohistochemis-
try. Increased nuclear localization of HIF1-α upon CoCl2 exposure confirms the induction of hypoxia (Fig. 7D).
In previous studies, it has been shown that, hypoxic signalling activation results in significant increase in EVs 
release in breast cancer cells38. Therefore, the aim of this study was to quantify EVs by designed biosensors for 
normoxia and hypoxia conditions. Both DPV and EIS results indicate a significant change in exosome secretion 
after exposure to hypoxia. Figure 7B shows the exosome concentration relative to normoxic control based on 
DPV data and calibration curve. The ratio between exosome secretion levels was calculated as 1.23. Similarly, 
Fig. 7D shows the normalized exosome concentration with respect to normoxic control and has the exact same 
ratio of 1.23. The reported exosome secretion change with CoCl2 induced hypoxia was 1.77-fold increase with 
NTA analysis from MCF-7 cells38. Therefore the experimental findings support the literature.
Discussion
This paper describes a label-free electrochemical detection method for EVs based on the transmembrane CD-81 
biomarker. The designed biosensor neither requires any expensive microfabrication steps nor lengthy experi-
mental steps. Unlike ELISA, a lengthy procedure that does not provide reproducible results, and has a very high 
LOD (2.84 × 1014 EVs/ml), our sensor enables a sensitive detection of EVs with a LOD of 77 EVs/ml with a RSD% 
smaller than 9.6%. Moreover, the reported LOD of the biosensor is lower than any biosensors reported for EVs 
Figure 6. Results of the biosensor selectivity study showing the effect of RhD immobilization on Anti-CD81 
Ab immobilized electrodes. Nyquist plots (A) and bar graphs representing Rct values calculated from simulation 
results (B). Differential pulse voltammogram (B), and bar graphs representing IpA values. Data are expressed as 
mean ± standard deviation of three measurements. Experimental steps are detailed in methods section.
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detection. We also demonstrated the selectivity of the biosensor for CD-81 by using a blood-abundant protein, 
RhD as control considering the future applications of the sensor on detection of EVs inside blood.
In this study, we have also demonstrated for the first time in literature that, this label-free, low-cost biosensor 
based on commercially available, disposable screen printed electrodes can be used for detection of CoCl2 induced 
hypoxia triggered enhanced EVs secretion. MCF-7 cell line was used as a model breast cancer cell line and 
hypoxic conditions were maintained for three days. The exosome secretion level was calculated to be increased by 
1.23-fold after CoCl2 exposure compared to normoxic conditions. The proposed biosensor does not require any 
labelling procedures, expensive microfabrication techniques and nanoparticle functionalization, therefore pro-
vides a very simple strategy with a superior limit of detection. Therefore, we believe that, this label-free biosensor 
has the potential to be integrated with cell culture platforms to monitor changes in EVs secretion triggered by 
relevant parameters such as oxygen tension.
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